Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 8;13(6):1056-1062.
doi: 10.1093/ckj/sfz112. eCollection 2020 Dec.

Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study

Affiliations

Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study

Douglas S Fuller et al. Clin Kidney J. .

Abstract

Background: Prior studies have developed a chronic kidney disease-mineral and bone disorder (CKD-MBD) composite score based on combinations of calcium (Ca), phosphorus (P) and parathyroid hormone (PTH) that have been shown to be associated with an increased risk of clinical outcomes in the USA. We examined this association in a contemporary, international cohort of hemodialysis patients.

Methods: We studied 19 313 patients surviving ≥12 months in the Dialysis Outcomes and Practice Patterns Study Phases 3-5 (2005-15) from Europe, Canada and the USA. The CKD-MBD composite score was defined as the number of markers above target levels (P, 3.5-5.5 mg/dL; Ca, 8.4-10.2 mg/dL; PTH, 150-600 pg/mL). Using Cox models, we estimated hazard ratios (HRs) for death and a composite event (death or hospitalization), contrasting MBD 2/3 (2-3 parameters above target) with MBD 0 (all in target), adjusted for a disease risk score (DRS).

Results: MBD 2/3 above target was observed in 10-14% of patients across regions and was associated with greater DRS-adjusted mortality {HR 1.41 [95% confidence interval (CI) 1.10-1.82]} and composite events [HR 1.23 (95% CI 1.10-1.38)] in the USA compared with MBD 0; the mortality association was stronger for patients ≥ 65 years of age [HR 1.82 (95% CI 1.28-2.58)] compared with patients <65 years of age [HR 1.11 (95% CI 0.80-1.55)]. HRs observed in Canada and Europe were generally consistent but weaker. Estimates for MBD 2/3 outside target (above or below) were slightly lower in all regions.

Conclusions: Simultaneous consideration of Ca, P and PTH may help in identifying patients on dialysis with a higher risk of major clinical outcomes related to CKD-MBD.

Keywords: CKD-MBD; DOPPS; calcium; hemodialysis; parathyroid hormone; phosphorus.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
HRs for MBD 2/3 above target versus MBD 0, by region. CAN, Canada; DRS, disease risk score; EUR, Europe. Europe includes Belgium, France, Germany, Italy, Spain, Sweden and the UK. Composite outcome defined as death or hospitalization. DRS adjustment variables include age, Liu’s comorbidity index, years with ESRD (vintage), serum albumin, hemoglobin, BMI, single-pool Kt/V, number of patients dialyzing in the study facility, male sex, black race (USA only), data source (electronic health record versus other; USA only), primary cause of ESRD, smoking history (ever versus never smoked), hypertension, history of fracture, hospitalization within 120 days prior to the index date, DOPPS study phase and country (Europe only).
FIGURE 2
FIGURE 2
HRs for MBD 2/3 outside target versus MBD 0, by region. CAN, Canada; DRS, disease risk score; EUR, Europe. Europe includes Belgium, France, Germany, Italy, Spain, Sweden and the UK. Composite outcome defined as death or hospitalization. DRS adjustment variables include age, Liu’s comorbidity index, years with ESRD (vintage), serum albumin, hemoglobin, body mass index, single-pool Kt/V, number of patients dialyzing in the study facility, male sex, black race (USA only), data source (electronic health record versus other; USA only), primary cause of ESRD, smoking history (ever versus never smoked), hypertension, history of fracture, hospitalization within 120 days prior to the index date, DOPPS study phase and country (Europe only) .

References

    1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–S201 - PubMed
    1. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771–780 - PubMed
    1. St Peter WL, Li Q, Liu J et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009; 4: 354–360 - PMC - PubMed
    1. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149–156 - PubMed
    1. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 2006; 70: 1358–1366 - PubMed

LinkOut - more resources